Occam Places Allison August as CMO at Comanche Bio
Comanche Biopharma is a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Investors include GV, F-Prime, and Population Health Partners. The company has appointed Allison August, M.D. as Chief Medical Officer. Dr. August, an obstetrician-gynecologist, brings more than 25 years of clinical experience to her position at Comanche Biopharma.
August joins Comanche Biopharma from Moderna, where she was Vice President of Clinical Development, Infectious Diseases, and spent over five years in various roles with increasing responsibility for the development of mRNA-based vaccines and the first mRNA-encoded monoclonal antibody.
Before moving to the biopharma industry, August was an academic and private practice obstetrician-gynecologist. Her academic career included faculty positions at the Brown University Medical School and adjunct faculty at Harvard Medical School affiliated hospitals. Dr. August holds a B.A. in the History of Religion from Bryn Mawr College and an M.D. from the University of Chicago
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.